Cost (US $) estimates (expected value [range])
| Parameters | United States | United Kingdom | China |
|---|---|---|---|
| Price of sunitinib per 50 mg | 601.9 (301–601.9)# [28] | 145.7 (72.87–145.7) # [35] | 275.2 (137.6–275.2) # [21] |
| Price of ipilimumab per 50 mg | 7324 (3662 – 7324) # [28] | 4875 (2438 – 4875) # [26] | 4655 (2328–7324)a # |
| Price of nivolumab per 100 mg | 2670 (1335 – 2670) # 31 | 1426 (713.1–1426) # [26] | 1362 (680.9–1362) # |
| Cost of follow-up and monitoring per cycle | 422 (348.1–495.8) [30] | 75.78 (48.32–103.2) [35] | 6.13 (4.9–8.58) [21] |
| Cost of second-line active treatment per patient | 27,936 (26,429 – 29,443) [32] | 15,012 (14,793 – 15,231) [35] | 21,081 (11,927 – 26,628) [21] |
| Cost of BSC per cycle | 1213 (987–1438) [31] | 88.23 (70.53–105.9) [35] | 52.53 (49.1–69.21) [39] |
| Cost of terminal care per patient | 10,713 (8570 – 12,856) [24, 32] | 10,366 (8566 – 12,849) [19] | 1893 (1564–2346) [45] |
| Cost of managing AEs (grade ≥ 3) per event | |||
| Fatigue | 139 (1.06–2018) [32–34] | 483.6 (0–967.2) [38] | 110.3 (82.72–137.9) [21] |
| Hypertension | 201.9 (1.08–6533) [32–34] | 27.3 (0–54.6) [38] | 12.35 (9.26–15.44) [21] |
| Anemia | 4638 (3326 – 5949) [32–34] | 3242 (3097 – 3388) [38] | 508.2 (381.2–635.3) [21] |
| Palmar–plantar erythrodysesthesia | 118.8 (3.43–1748) [32–34] | 131.3 (98.48–164.1) [19] | 15.21 (8.85–21.57) [40] |
| Thrombocytopenia | 4014 (1716 – 9391) [34] | 4927 (4764 – 5091) [38] | 3395 (2546 – 4244) [21] |
| Cost of drug administration per unit | 292 (219–365) [16] | 405.3 (304–506.7) [26] | 17.65 (13.24–22.06) [21] |
aThe prices were assumed by multiplying the price of ipilimumab in UK and the ratio of the price of nivolumab between UK and China
# The ranges were assumed